I don't hv facility to buy spore shares. But had tracked both and if you look at market share.. They are global player. Stemcell products are selling very well globally. However stemlfe is umbilical cord savings .. Like blood bank savings. Growing but slowly and management not steady ... And shows in price dropping
made 200% profit from stemlife. True, Cordlife in Singapore is doing better and good return for investors with S'poreans more into this bio-tech companies. Msia is very slow. Stemlife after one of the Singaporeans bought in, the price has gone up. But my question is where is Hong Leong Tan Sri Quah LC? He has shares in Stemlife. Last I heard is 5-8%. Isn't he investing as this is a money making machine as he likes to play the game, or that he has Singaporeans to compete with?
Mining strategy: Fair price shall be 28-30sen hovering on 1st level target, 26sen region for 2nd level option, conditional retracement expected in near terms
Wow! So glad I sold mine at 50.5 sen! Now drop of over 20%! Whoever bough high.. Don't average down yet. Look at other stocks of around 30 sen to go in to regain paper lost here. All the best!
I see... KUALA LUMPUR: Stemlife Bhd 29.44 million shares valued at RM17.66mil were traded off-market at 60 sen each on Friday. The traded price was 21.5 sen above the Thursday’s close of 38.5 sen. At 4.54pm on Friday its shares were up 3.5 sen to 42 sen. According to the stock market data, the 29.44 million shares accounted for an 11.89% stake based on its paid-up of 247.5 million shares. Data showed that Cordlife Group Ltd owned 19.92% stake in the group followed by Berjaya Corp Bhd at 12.12%.. Stemlife is a life-science company which offers stem cell therapies and consultancy services.
Singapore-listed Cordlife Group announced on Monday that it has acquired a further 11.89 per cent stake in StemLife, an associated company of Cordlife. This brings Cordlife's total stake to about 31.81 per cent in StemLife.
Cordlife, a provider of cord blood and tissue banking services said in a statement that a cash payment of RM17.66 million was made for the stake in Malaysia-listed StemLife.
StemLife provides cord-blood banking services.
Cordlife also aspires to be a multi-product healthcare company, with a focus on the mother and child segment.
Stemlife (STEM MK) Technical BUY with +25.0% potential return Last price : RM0.42 Resistance : RM0.525 Support : RM0.380 Stop-loss: RM0.360 BUY with a target price of RM0.525 with a stop loss below RM0.360. Following a sharp uptrend since 28 Aug 13, STEM touched its 52-week high of RM0.525 on 4 Oct 13. The share price has since then retraced and stabilised within the range of RM0.380-0.400. However, STEM recorded a surge of 3.5 sen (+9.1%) and a gap up last Friday. Although there was no significant spike in volume last Friday, STEM’s RSI surpassed the 50pt threshold and a bullish crossover in MACD was recorded, suggesting that the buying momentum is building up. We expect the share price to retest the previous high of RM0.430 which, if violated, would likely spur fresh buying interest and propel the stock toward our target of RM0.525 in the medium term.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
member41
3,718 posts
Posted by member41 > 2013-11-18 23:08 | Report Abuse
A doctor fren told me the cord blood business is doing well. Decided to accumulate some. Cordlife too.